ESMO 2023 | Prognostic score in early HR+/HER2- breast cancer: RS, factors, mutations, histology

Oleg Gluz, MD, Evangelical Hospital Bethesda, Moenchengladbach, Germany, discusses the Phase II WSG-ADAPT HR+/HER- trial (NCT01779206) for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer, assessing the prognostic impact of clinical, immunohistochemical (IHC), and genomic markers. The study included 4,491 patients, with outcomes varying in endocrine therapy (ET) and chemotherapy (CT) cohorts. Tumor/nodal stage, Recurrence Score (RS), and progesterone receptor (PR) expression were prognostic in the entire cohort. In ET-treated patients, T-stage, RS, and ER expression were significant, while in CT-treated patients, additional factors like histology (invasive lobular carcinoma – ILC), G2-3, and IHC4 were included. A prognostic score combining various factors had a 66% ROC AUC in the CT cohort, revealing worse prognosis for high-risk ILC cases. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.